Balañá, Carmen <br/><br/>
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?  [electronic resource] 

 -  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico  Mar 2011 
 - 209-10 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1699-3055 
<br/><br/><label>Standard No.: </label>10.1007/s12094-011-0642-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--therapeutic use<br/>Bevacizumab<br/>Brain Neoplasms--drug therapy<br/>Drug Approval--legislation & jurisprudence<br/>Europe<br/>Glioma--drug therapy<br/>Humans<br/>Neoplasm Recurrence, Local--drug therapy<br/>Randomized Controlled Trials as Topic